AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Tungstate Treatment of Inflammatory Bowel Disease-Associated Dysbiosis

Technology Benefits
Tungstate has no adverse side effects unlike current anti-inflammatory therapies such as anti-TNF alpha antibodies A targeted therapy that only gets rid of the bad microbes, while leaving beneficial microbes unharmed
Technology Application
Treatment for Irritable bowel disease
Detailed Technology Description
Conditions of intestinal inflammation, from disease states such as inflammatory bowel disease, can lead to microbial imbalance (dysbiosis) characterized by the representation of microbes that are otherwise not found in the intestine, such as E. coli. This increased relative abundance of facultative anaerobic bacteria, such as E. coli is thought to exacerbate inflammatory bowel disease symptoms and duration. Researchers at the University of California, Davis have found that oral treatment of tungstate is an effective treatment of IBD. Administration of Tungstate diminished the total number of E. coli strains and allowed both facultative and obligate anaerobe strains to recover to similar levels, which indicated that tungsten blunts the fitness advantage conferred by anaerobic respiration as tungstate substitutes as a competitive antagonist for molybdenum in molybdopeterin cofactor of reductases used by E. coli to perform anaerobic respiration. These results suggest that oral administration of soluble tungsten salts can aid in restoring a normal micrbiota composition by specifically inhibiting anaerobic respiratory pathways operational only during gut inflammation. Treatment with tungsten salts has further been shown to reduce morbidity in mouse models of IBD.
Application No.
20160158282
Others

Tech ID/UC Case

23666/2013-610-0


Related Cases

2013-610-0

*Abstract

Researchers at the University of California, Davis have found that oral treatment of tungstate is an effective treatment of Inflammatory bowel disease.

*IP Issue Date
Jun 9, 2016
*Principal Investigator

Name: Andreas Baumler

Department:


Name: Sebastian Winter

Department:

Country/Region
USA

For more information, please click Here
Mobile Device